BR112015024605A2 - sistemas e métodos para a produção visada de proteína terapêutica dentro de célula alvo - Google Patents

sistemas e métodos para a produção visada de proteína terapêutica dentro de célula alvo

Info

Publication number
BR112015024605A2
BR112015024605A2 BR112015024605A BR112015024605A BR112015024605A2 BR 112015024605 A2 BR112015024605 A2 BR 112015024605A2 BR 112015024605 A BR112015024605 A BR 112015024605A BR 112015024605 A BR112015024605 A BR 112015024605A BR 112015024605 A2 BR112015024605 A2 BR 112015024605A2
Authority
BR
Brazil
Prior art keywords
systems
methods
disease
therapeutic protein
target cells
Prior art date
Application number
BR112015024605A
Other languages
English (en)
Inventor
r scholz Matthew
Original Assignee
Oisin Biotechnologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oisin Biotechnologies filed Critical Oisin Biotechnologies
Publication of BR112015024605A2 publication Critical patent/BR112015024605A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

“sistemas e métodos para a produção visada de proteína terapêutica dentro de célula alvo” resumo proporcionam-se construções de expressão nucleicos à base de ácido para a produção de uma proteína alvo terapêutico dentro de uma célula que está associada com o envelhecimento, doença, uma outra condição. são também proporcionados vectores e sistemas para a entrega dos expressão à base de ácido nucleico construções, assim como métodos para utilizar tais nucleicos construções de expressão à base de ácido, vectores e sistemas para a redução, prevenção, e / ou eliminar o crescimento e / ou sobrevivência de uma célula à idade, doença-, ou condição associada à e para o tratamento de uma doença ou condição que é associada com uma idade, doença, ou condição associada às células. 13/1 1/1
BR112015024605A 2013-03-24 2014-03-24 sistemas e métodos para a produção visada de proteína terapêutica dentro de célula alvo BR112015024605A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361804716P 2013-03-24 2013-03-24
PCT/US2014/031638 WO2014160661A2 (en) 2013-03-24 2014-03-24 Systems and methods for the targeted production of a therapeutic protein within a target cell

Publications (1)

Publication Number Publication Date
BR112015024605A2 true BR112015024605A2 (pt) 2017-07-18

Family

ID=51625661

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015024605A BR112015024605A2 (pt) 2013-03-24 2014-03-24 sistemas e métodos para a produção visada de proteína terapêutica dentro de célula alvo

Country Status (10)

Country Link
US (3) US20160051700A1 (pt)
EP (1) EP2978854A4 (pt)
KR (3) KR20180118259A (pt)
CN (1) CN105518149A (pt)
AU (3) AU2014241622A1 (pt)
BR (1) BR112015024605A2 (pt)
CA (1) CA2940123C (pt)
HK (1) HK1218935A1 (pt)
MX (2) MX2015013590A (pt)
WO (1) WO2014160661A2 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US10940169B2 (en) 2015-11-30 2021-03-09 Joseph E. Kovarik Method for reducing the likelihood of developing cancer in an individual human being
US10835560B2 (en) 2013-12-20 2020-11-17 Joseph E. Kovarik Reducing the likelihood of skin cancer in an individual human being
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US20140189897A1 (en) 2011-06-21 2014-07-03 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
WO2013158664A2 (en) 2012-04-17 2013-10-24 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
US10279018B2 (en) 2012-12-03 2019-05-07 Unity Biotechnology, Inc. Immunogenic compositions for inducing an immune response for elimination of senescent cells
US11026982B2 (en) 2015-11-30 2021-06-08 Joseph E. Kovarik Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11642382B2 (en) 2013-12-20 2023-05-09 Seed Health, Inc. Method for treating an individual suffering from bladder cancer
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11213552B2 (en) 2015-11-30 2022-01-04 Joseph E. Kovarik Method for treating an individual suffering from a chronic infectious disease and cancer
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11529379B2 (en) 2013-12-20 2022-12-20 Seed Health, Inc. Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
US11672835B2 (en) 2013-12-20 2023-06-13 Seed Health, Inc. Method for treating individuals having cancer and who are receiving cancer immunotherapy
WO2017223107A1 (en) * 2016-06-20 2017-12-28 Unity Biotechnology, Inc. Genome modifying enzyme therapy for diseases modulated by senescent cells
US11525146B2 (en) 2017-01-09 2022-12-13 Oisin Biotechnologies, Inc. Expression constructs, fusogenic lipid-based nanoparticles and methods of use thereof
EP3743112A4 (en) * 2018-01-23 2021-11-03 Ascend Biopharmaceuticals Ltd IMPROVED VIRAL RELEASE FORMULATION
WO2019204666A1 (en) * 2018-04-18 2019-10-24 Oisin Biotechnologies, Inc. Fusogenic lipid nanoparticles and methods for the manufacture and use thereof for the target cell-specific production of a therapeutic protein and for the treatment of a disease, condition, or disorder associated with a target cell
WO2020023183A1 (en) * 2018-07-24 2020-01-30 So Young Life Sciences Corporation Use of liposomes to deliver a protein and a gene encoding the protein to a live cell
EP3653716A1 (en) * 2018-11-19 2020-05-20 HSF Pharmaceuticals Replication-competent controlled alpha-herpesvirus virus vectors and uses therefore
CN112521511B (zh) * 2020-12-07 2023-03-14 中山大学 一种含EB病毒gB蛋白的自组装纳米颗粒及其制备方法与应用
WO2022245984A1 (en) * 2021-05-19 2022-11-24 Shape Therapeutics Inc. Compositions and methods for modulating payload expression at a transcriptional level
KR20230136406A (ko) 2022-03-18 2023-09-26 단국대학교 천안캠퍼스 산학협력단 Fast 유전자를 포함하는 레트로바이러스 벡터 및 암 유전자치료제로서의 용도
WO2024073370A2 (en) * 2022-09-27 2024-04-04 The Regents Of The University Of California Methods to rejuvenate human cells through transcriptional reprogramming

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009298A1 (en) 1990-11-23 1992-06-11 Peptide Technology Ltd. The delay, prevention and/or reversal of cell senescence
CA2325088A1 (en) 2000-12-01 2002-06-01 Fusogenix Inc. Novel membrane fusion proteins derived from poikilothermic reovirus
CA2460095A1 (en) * 2001-06-13 2003-12-19 Eastern Virginia Medical School Methods for targeted expression of therapeutic nucleic acid
CN100361710C (zh) * 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
WO2008154644A1 (en) 2007-06-12 2008-12-18 Case Western Reserve University Targeted cell death
EP2789684B1 (en) 2008-05-23 2016-12-21 Siwa Corporation Methods and compositions for facilitating regeneration
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
US10227386B2 (en) 2010-09-29 2019-03-12 Entos Pharmaceuticals Inc. Recombinant polypeptides for membrane fusion and uses thereof
US20140189897A1 (en) * 2011-06-21 2014-07-03 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
US11525146B2 (en) * 2017-01-09 2022-12-13 Oisin Biotechnologies, Inc. Expression constructs, fusogenic lipid-based nanoparticles and methods of use thereof

Also Published As

Publication number Publication date
MX2015013590A (es) 2016-06-06
US20200009268A1 (en) 2020-01-09
WO2014160661A2 (en) 2014-10-02
AU2021200496A1 (en) 2021-02-25
CN105518149A (zh) 2016-04-20
KR20200074283A (ko) 2020-06-24
KR20180118259A (ko) 2018-10-30
EP2978854A2 (en) 2016-02-03
HK1218935A1 (zh) 2017-03-17
AU2014241622A1 (en) 2015-11-12
MX2019010735A (es) 2019-11-05
CA2940123C (en) 2023-10-10
US20160010110A1 (en) 2016-01-14
KR20160002848A (ko) 2016-01-08
US20160051700A1 (en) 2016-02-25
EP2978854A4 (en) 2017-01-11
WO2014160661A3 (en) 2014-12-31
AU2018220160A1 (en) 2018-09-13
AU2018220160B2 (en) 2021-05-20
CA2940123A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
BR112015024605A2 (pt) sistemas e métodos para a produção visada de proteína terapêutica dentro de célula alvo
BR112018073861A2 (pt) métodos de terapia de genes para doenças e condições relacionadas com a idade
CY1124742T1 (el) 4'-φθορο-νουκλεοσιδια, 4'-φθορο-νουκλοεοτιδια και αναλογα αυτων για τη θεραπευτικη αγωγη toy hcv
BR112015014752A2 (pt) compostos e métodos para modulação de cinase, e indicações para isto
CY1121511T1 (el) Ενωσεις και μεθοδοι για διαμορφωση κινασων και ενδειξεις αυτων
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
EA201990202A1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2
CY1126074T1 (el) Περιοχες gla ως παραγοντες στοχευσης
CU20150119A7 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
BR112016016658A2 (pt) proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
UY35596A (es) Compuestos para la modulación de quinasas, y sus indicaciones
CY1120354T1 (el) Αναστολεις ακυλοτρανσφερασης της διακυλογλυκερολης 2 για χρηση στη θεραπεια μεταβολικων και συγγενων διαταραχων
EA201400990A1 (ru) Ингибиторы диацилглицеринацилтрансферазы 2
BR112017004349A2 (pt) terapia com gene de globina para o tratamento de hemoglobinopatias
BR112017000470A2 (pt) composto, composição farmacêutica, método para modular atividade, método para tratar uma afecção
BR112016027871A2 (pt) composição para melhorar a memória, a função de aprendizado e/ou função cognitiva
BR112016004095A2 (pt) administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores
BR112017012504A2 (pt) derivados de piperidina como inibidores de hdac1/2
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
CL2016001510A1 (es) Células madre derivadas de musculo de mamifero
BR112018017322A2 (pt) proteínas de fusão de enzima lisossômica terapêuticas direcionadas, formulações associadas e usos das mesmas
MX2020011500A (es) Moléculas pequeñas para inhibir la actividad de quimiocinas, la actividad de una cinasa y/o el crecimiento de células cancerosas.
UY35438A (es) Procedimiento para preparar inhibidores de la glucosilceramida sintasa.
BR112014017160A2 (pt) sistema de administração de fragrância duradoura

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.